Feb 26, 2026 09:10AM
Feb 26, 2026 09:10AM
Feb 23, 2026 08:50AM
Feb 23, 2026 08:50AM
Jan 9, 2026 09:00AM
Dec 30, 2025 09:15AM
Dec 30, 2025 09:15AM Akari Therapeutics Issues 2025 End of Year Letter to Shareholders
Dec 23, 2025 08:30AM
Dec 23, 2025 08:30AM
Dec 18, 2025 08:30AM
Dec 16, 2025 09:29AM
Dec 16, 2025 09:29AM
Dec 9, 2025 08:40AM
Dec 9, 2025 08:40AM Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer
Dec 4, 2025 09:00AM
Nov 18, 2025 08:35AM
Nov 18, 2025 08:35AM
Nov 18, 2025 08:35AM
Nov 18, 2025 08:35AM
Nov 10, 2025 08:32AM
Nov 10, 2025 08:30AM Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhib
Nov 4, 2025 09:25AM
Oct 30, 2025 08:35AM
Oct 30, 2025 08:35AM
Oct 15, 2025 08:30AM
Oct 15, 2025 08:30AM
Oct 9, 2025 08:46AM
Oct 9, 2025 08:45AM Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1
Oct 3, 2025 09:30AM
Sep 24, 2025 08:46AM
Sep 24, 2025 08:45AM
Sep 17, 2025 08:45AM
Sep 17, 2025 08:45AM
Jul 29, 2025 09:15AM
Jul 23, 2025 08:55AM Akari Therapeutics advances research on cancer drug payload PH1
Jul 23, 2025 08:55AM
Jun 18, 2025 08:50AM
Jun 18, 2025 08:50AM
May 29, 2025 09:15AM
May 15, 2025 05:01PM
May 15, 2025 08:05AM
May 1, 2025 08:48AM Akari Therapeutcis (AKTX) Appoints Mark F. Kubik as Head of Business Development - Oncology
May 1, 2025 08:45AM
Apr 22, 2025 09:05AM
Apr 16, 2025 08:00AM
Mar 20, 2025 08:35AM
Mar 20, 2025 08:35AM
Mar 3, 2025 09:02AM
Mar 3, 2025 09:00AM Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules
Feb 19, 2025 09:00AM

1,168,522 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All